Japan’s CBD Industry Recieves First Investments From Publicly Listed Companies Following
13.12.2024 10:19:09 CET | news aktuell GmbH | Press release
AstraSana Japan Co., Ltd. has formed a capital and business alliance with Japan’s GSI Creos Corporation, bolstered by their investment. This partnership will enhance the wholesale distribution of CBD raw materials across Japan, leveraging the strengths of both companies.

(Kloten / Tokio) Through this alliance, the AstraSana Group, headquartered in Switzerland, will establish a robust supply chain to deliver Swiss-made, high-quality CBD raw materials across Japan, with a mission is to ensure customers receive safe, reliable products of the highest standard.
Through this alliance, AstraSana Group (headquartered in Switzerland) will establish a stable supply chain to deliver Swiss-made, high-quality CBD raw materials nationwide in Japan. We aim to provide safe and reliable products to our customers.
By leveraging GSI Creos’ extensive resources and networks, AstraSana says it will offer even higher-quality services to customers. Based on this robust partnership, it will actively contribute to the growth and development of the CBD market through various approaches.
“At AstraSana Japan, we prioritize safety through third-party analyses, ensure the delivery of superior-quality products, and place customer trust and satisfaction at the heart of everything we do. We are dedicated to enhancing customers’ ‘Quality of Life’ (QOL) while staying at the forefront of technological innovation.
The Potential of CBD in the Japanese Market
CBD (Cannabidiol), a hemp-derived compound, is legally recognized as a safe material in Japan. With global demand on the rise, the opportunities for CBD in the Japanese market are rapidly expanding. This collaboration strengthens AstraSana’s supply chain, addressing past challenges, and further promotes the availability of safe and reliable CBD products across the country.
About GSI Creos Corporation
Website: Home | GSI Creos Corporation GSI Creos is an innovative trading company with nine domestic and 24 international bases. Operating globally in both “textiles” and “industrial products,” their business spans a diverse range, including textile raw materials, apparel, chemicals, hobby materials, machinery, semiconductor components, and nanotechnology. Guided by the purpose, “Creating quality of life for the next generation,” GSI Creos champions ESG management to tackle social challenges and promote human well-being.
About AstraSana Group / AstraSana Holding AG
Website: AstraSana Holding AG The AstraSana Group is a leading global company specializing in cannabinoid raw materials and medical cannabis. Headquartered in Zurich, Switzerland, AstraSana Holding AG operates through affiliates in the Czech Republic, the UK, and Japan. Collaborating with partners across Europe and South America, including Belgium, the group continues to expand its worldwide presence.
Contacts
Yves Antoniazzi
info@astrasana.comAbout news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
FRITZ: YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press release
More than half of consumers in Norway mistrust routers from Chinese manufacturers (59%) Many mistrust devices made in the USA European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom